Döhner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.

PubMed  PubMed Central  Google Scholar 

Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol. 2013;26(3):253–9.

PubMed  PubMed Central  Google Scholar 

O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–67.

CAS  PubMed  Google Scholar 

Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–22.

CAS  PubMed  Google Scholar 

Sendker S, Reinhardt D, Niktoreh N. Redirecting the immune microenvironment in acute myeloid leukemia. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13061423.

PubMed  Google Scholar 

Zhou Q, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116(14):2484–93.

CAS  PubMed  PubMed Central  Google Scholar 

Graf M, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol. 2005;84(5):287–97.

CAS  PubMed  Google Scholar 

Bewersdorf JP, Zeidan AM. Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment? Expert Rev Anticancer Ther. 2022;22(3):239–41.

CAS  PubMed  Google Scholar 

Curti A, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007;109(7):2871–7.

CAS  PubMed  Google Scholar 

Schnorfeil FM, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93.

PubMed  PubMed Central  Google Scholar 

Daver N, et al. Efficacy, safety, and biomarkers of response to Azacitidine and Nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370–83.

CAS  PubMed  Google Scholar 

Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. 2022. https://doi.org/10.3390/cells11142249.

PubMed  PubMed Central  Google Scholar 

Yang H, Xun Y, You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark Res. 2023;11(1):15.

PubMed  PubMed Central  Google Scholar 

Stahl M, Goldberg AD. Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets. Curr Oncol Rep. 2019;21(4):37.

PubMed  Google Scholar 

Maslak PG, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224–34.

CAS  PubMed  PubMed Central  Google Scholar 

Qazilbash MH, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017;31(3):697–704.

CAS  PubMed  Google Scholar 

Anguille S, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130(15):1713–21.

CAS  PubMed  PubMed Central  Google Scholar 

Fløisand Y, et al. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023;37(9):1842–9.

PubMed  Google Scholar 

Jiang Z, et al. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14(1):180.

CAS  PubMed  PubMed Central  Google Scholar 

Sallman DA, et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;41(15):2815–26.

CAS  PubMed  PubMed Central  Google Scholar 

Bewersdorf JP, Stahl M, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Rev Anticancer Ther. 2019;19(5):393–404.

CAS  PubMed  Google Scholar 

Taghiloo S, Norozi S, Asgarian-Omran H. The effects of PI3K/Akt/mTOR signaling pathway inhibitors on the expression of immune checkpoint ligands in acute myeloid leukemia cell line. Iran J Allergy Asthma Immunol. 2022;21(2):178–88.

PubMed  Google Scholar 

Chen Y, et al. A perspective of immunotherapy for acute myeloid leukemia: current advances and challenges. Front Pharmacol. 2023;14:1151032.

CAS  PubMed  PubMed Central  Google Scholar 

Farrokhi M, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1–164.

Google Scholar 

Christopher MJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379(24):2330–41.

CAS  PubMed  PubMed Central  Google Scholar 

Le Dieu R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114(18):3909–16.

PubMed  PubMed Central  Google Scholar 

Yoyen-Ermis D, et al. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS. Sci Rep. 2019;9(1):11697.

PubMed  PubMed Central  Google Scholar 

Huang S, et al. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia. Cancer Biol Ther. 2023;24(1): 2278229.

PubMed  PubMed Central  Google Scholar 

Pentcheva-Hoang T, et al. B7–1 and B7–2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004;21(3):401–13.

CAS  PubMed  Google Scholar 

Re F, et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Exp Hematol. 2002;30(2):126–34.

CAS  PubMed  Google Scholar 

Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004.

CAS  PubMed  PubMed Central  Google Scholar 

Rezaei M, et al. TIM-3 in leukemia; immune response and beyond. Front Oncol. 2021;11: 753677.

CAS  PubMed  PubMed Central  Google Scholar 

Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–52.

CAS  PubMed  Google Scholar 

Aval OS, et al. Galectin-9: a double-edged sword in Acute Myeloid Leukemia. Ann Hematol. 2025;9:1–4.

Google Scholar 

Han Y, et al. Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells. Front Immunol. 2018;9:2227.

PubMed  PubMed Central  Google Scholar 

Paczulla AM, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572(7768):254–9.

CAS  PubMed  PubMed Central  Google Scholar 

Baragaño Raneros A, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2015;16(1):71–82.

PubMed  Google Scholar 

Stringaris K, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836–47.

PubMed  PubMed Central  Google Scholar 

Szczepanski MJ, et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011;96(9):1302–9.

CAS  PubMed